The majority of patients with age-related macular degeneration benefitted from a regimen with bevacizumab as the first-line therapy, and in this video, Shriji Patel, MD, assistant professor of ophthalmology and co-fellowship director of vitreoretinal diseases and surgery at the Vanderbilt Eye Institute, explains why this study was undertaken and his thoughts for future research.
“We’re doing this because there’s been a lot of talk lately about this idea of doing step therapy, where insurance companies or Medicare could mandate what drug physicians would start patients on,”
Uncategorized